The company has received additional funding from NLC InfiCure Bio and Partnerinvest Övre Norrland.

The funding will be used to speed up the validation of additional indications in the NIF mouse, states the company. “This is a golden opportunity to broaden our customer base and increase the revenue of the company,” it says in its press release.

“With our unique model pharmaceutical companies may test if their pharmaceuticals will work against liver fibrosis – and soon they may also test if the pharmaceuticals are effective on other fibrosis, like fibrosis in the kidneys,” says Sofia Mayans, CEO of InfiCure.

Read also:

She is the new Chairman of Inficure Bio’s board

InfiCure collaborates with CSL